David T. Bearden

2.6k total citations · 1 hit paper
39 papers, 2.0k citations indexed

About

David T. Bearden is a scholar working on Epidemiology, Infectious Diseases and Applied Microbiology and Biotechnology. According to data from OpenAlex, David T. Bearden has authored 39 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Epidemiology, 15 papers in Infectious Diseases and 12 papers in Applied Microbiology and Biotechnology. Recurrent topics in David T. Bearden's work include Antibiotic Use and Resistance (12 papers), Antimicrobial Resistance in Staphylococcus (9 papers) and Urinary Tract Infections Management (7 papers). David T. Bearden is often cited by papers focused on Antibiotic Use and Resistance (12 papers), Antimicrobial Resistance in Staphylococcus (9 papers) and Urinary Tract Infections Management (7 papers). David T. Bearden collaborates with scholars based in United States and Canada. David T. Bearden's co-authors include Manjunath P. Pai, Kevin W. Garey, Katie J. Suda, Robin S. Turpin, M Rege, Jessina C. McGregor, Larry H. Danziger, Keith A. Rodvold, Miriam Elman and Melinda M. Neuhauser and has published in prestigious journals such as Clinical Infectious Diseases, The American Journal of Medicine and Antimicrobial Agents and Chemotherapy.

In The Last Decade

David T. Bearden

38 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study

2006 886 citations Kevin W. Garey, M Rege et al. Clinical Infectious Diseases profile →

Peers

Countries citing papers authored by David T. Bearden

Since Specialization

Citations

This map shows the geographic impact of David T. Bearden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Bearden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Bearden more than expected).

Fields of papers citing papers by David T. Bearden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Bearden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Bearden. The network helps show where David T. Bearden may publish in the future.

Co-authorship network of co-authors of David T. Bearden

This figure shows the co-authorship network connecting the top 25 collaborators of David T. Bearden. A scholar is included among the top collaborators of David T. Bearden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. Bearden. David T. Bearden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Frequency and Characteristics of Patients Prescribed Antibiotics on Admission to Hospice Care 2021 ·Journal of Palliative Medicine ·(unknown), Brie N. Noble, Mary Lynn McPherson, Jennifer Tjia, (unknown), (unknown), David T. Bearden, Jon P. Furuno	1
2	Development of a Longitudinal Curricular Evaluation Framework for Intra- and Interprofessional Teamwork 2021 ·Érudit (Université de Montréal) ·(unknown), (unknown), Martha Driessnack, Jared P. Austin, (unknown), (unknown), David T. Bearden, Cynthia Taylor, (unknown), (unknown)	0
3	Professional and interprofessional differences in electronic health records use and recognition of safety issues in critically ill patients 2016 ·Journal of Interprofessional Care ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), David T. Bearden, Vishnu Mohan, Jeffrey A. Gold	21
4	Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients 2013 ·BMC Family Practice ·Jessina C. McGregor, Miriam Elman, David T. Bearden, David H. Smith	41
5	A Nationwide Analysis of Antibiotic Use in Hospice Care in the Final Week of Life 2013 ·Journal of Pain and Symptom Management ·Jennifer S. Albrecht, Jessina C. McGregor, Erik K. Fromme, David T. Bearden, Jon P. Furuno	75
6	Variation in Antibiotic Susceptibility of Uropathogens by Age Among Ambulatory Pediatric Patients 2013 ·Journal of Pediatric Nursing ·Jessina C. McGregor, (unknown), David T. Bearden, David H. Smith, Susan E. Sharp, Judith A. Guzman‐Cottrill	11
7	Risk factors associated with linezolid-nonsusceptible enterococcal infections 2012 ·American Journal of Infection Control ·Jessina C. McGregor, Daniel M. Hartung, George P. Allen, Randy Taplitz, (unknown), (unknown), David T. Bearden	11
8	Efficacy of Oral β-Lactam versus Non-β-Lactam Treatment of Uncomplicated Cellulitis 2008 ·The American Journal of Medicine ·Karl Madaras‐Kelly, Richard Remington, Catherine M. Oliphant, Kevin L. Sloan, David T. Bearden	16
9	Comparative in vitro activities of topical wound care products against community-associated methicillin-resistant Staphylococcus aureus 2008 ·Journal of Antimicrobial Chemotherapy ·David T. Bearden, George P. Allen, J. Mark Christensen	17
10	Antimicrobial Dosing Considerations in Obese Adult Patients 2007 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Manjunath P. Pai, David T. Bearden	201
11	Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines 2007 ·Pharmacoepidemiology and Drug Safety ·Kevin W. Garey, Manjunath P. Pai, Katie J. Suda, Robin S. Turpin, M Rege, (unknown), David T. Bearden	53
12	Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study breakdown → 2006 ·Clinical Infectious Diseases ·Kevin W. Garey, M Rege, Manjunath P. Pai, (unknown), Katie J. Suda, Robin S. Turpin, David T. Bearden	886
13	Evaluation of antifungals in the surgical intensive care unit: a multi‐institutional study 2006 ·Mycoses ·Kevin W. Garey, Melinda M. Neuhauser, David T. Bearden, Joan P. Cannon, Russell E. Lewis, Layne O. Gentry, Dimitrios P. Kontoyiannis	22
14	Statewide Impact of Pharmacist-Delivered Adult Influenza Vaccinations 2005 ·American Journal of Preventive Medicine ·David T. Bearden, Thomas J. Holt	34
15	Clinical Pharmacokinetics of Quinupristin/Dalfopristin 2004 ·Clinical Pharmacokinetics ·David T. Bearden	22
16	Neutropenia After Single‐Dose Clindamycin for Dental Prophylaxis 2003 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Joseph Bubalo, (unknown), David T. Bearden	7
17	The effect of amiloride on amphotericin B-induced hypokalaemia 2001 ·Journal of Antimicrobial Chemotherapy ·David T. Bearden	7
18	Mechanism of Action of and Resistance to Quinolones 2001 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·David T. Bearden, Larry H. Danziger	69
19	Telithromycin: An Oral Ketolide for Respiratory Infections 2001 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·David T. Bearden, Melinda M. Neuhauser, Kevin W. Garey	19
20	Quinupristin‐Dalfopristin: An Overview 2000 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·George Delgado, Melinda M. Neuhauser, David T. Bearden, Larry H. Danziger	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact